Teva Takes Second Swing at Redo of ‘Skinny Label’ Drug Case

Oct. 8, 2021, 6:50 PM

Teva Pharmaceuticals USA Inc. is asking the full Federal Circuit to reconsider a fight over generic drug labeling that has already gone through the appeals court twice, warning “a wave of lawsuits” could threaten others bringing lower-cost medicines to market.

In August, a divided U.S. Court of Appeals for the Federal Circuit panel said language on Teva’s label for a generic version of GlaxoSmithKline PLC‘s Coreg heart drug encouraged doctors to prescribe it for federally unapproved uses. That decision came despite Teva’s use of “skinny labeling,” a practice where generic drugmakers leave a name-brand drug’s patented uses off their ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.